Biomimetic Wrinkled Prebiotic Microspheres with Enhanced Intestinal Retention for Hyperphosphatemia and Vascular Calcification

Overview

Journal Sci Adv

Date 2025 Jan 17

PMID 39823333

Authors

Bianxiang Hu

Yongqin Wang

Lei Yu

Lisha Cao

Shuai Liu

Linfang Zhong

Guobao Wang

Xiaozhong Qiu

Honghao Hou

Affiliations

Soon will be listed here.

Abstract

It is urgent for patients with chronic kidney disease (CKD) to develop a robust and facile therapy for effective control of serum phosphate and reasonable regulation of gut microbiota, which are aiming to prevent cardiovascular calcification and reduce cardiovascular complications. Here, bioinspired by intestinal microstructures, we developed biomimetic wrinkled prebiotic-containing microspheres with enhanced intestinal retention and absorption for reducing hyperphosphatemia and vascular calcification of CKD model rats. The resultant CSM@5 microspheres exhibited favorable phosphate binding capacity in vitro and could effectively reduce serum concentration of phosphorous in vivo. Through increasing the beneficial bacteria and decreasing the harmful bacteria in the intestinal tract, these prebiotic microspheres can modulate intestinal microbiota and then ameliorate vascular calcification notably. This feasible and robust approach may offer a potential and effective strategy for the treatment of hyperphosphatemia of CKD and prevention of its cardiovascular complications.

References

Musgrove J, Wolf M . Regulation and Effects of FGF23 in Chronic Kidney Disease. Annu Rev Physiol. 2019; 82:365-390. DOI: 10.1146/annurev-physiol-021119-034650. View

Deng H, Guan Y, Dong Q, An R, Wang J . Chitosan-based biomaterials promote bone regeneration by regulating macrophage fate. J Mater Chem B. 2024; 12(31):7480-7496. DOI: 10.1039/d3tb02563b. View

Isakova T, Xie H, Yang W, Xie D, Anderson A, Scialla J . Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305(23):2432-9. PMC: 3124770. DOI: 10.1001/jama.2011.826. View

Favero C, Carriazo S, Cuarental L, Fernandez-Prado R, Goma-Garces E, Perez-Gomez M . Phosphate, Microbiota and CKD. Nutrients. 2021; 13(4). PMC: 8070653. DOI: 10.3390/nu13041273. View

Foresto-Neto O, Ghirotto B, Camara N . Renal Sensing of Bacterial Metabolites in the Gut-kidney Axis. Kidney360. 2022; 2(9):1501-1509. PMC: 8786145. DOI: 10.34067/KID.0000292021. View

Plata C, Cruz C, Cervantes L, Ramirez V . The gut microbiota and its relationship with chronic kidney disease. Int Urol Nephrol. 2019; 51(12):2209-2226. DOI: 10.1007/s11255-019-02291-2. View

Amini Khiabani S, Asgharzadeh M, Kafil H . Chronic kidney disease and gut microbiota. Heliyon. 2023; 9(8):e18991. PMC: 10440536. DOI: 10.1016/j.heliyon.2023.e18991. View

Rahbar Saadat Y, Niknafs B, Hosseiniyan Khatibi S, Ardalan M, Majdi H, Bahmanpoor Z . Gut microbiota; an overlooked effect of phosphate binders. Eur J Pharmacol. 2019; 868:172892. DOI: 10.1016/j.ejphar.2019.172892. View

Asgharian M, Gholizadeh P, Kafil H, Ghojazadeh M, Samadi A, Soleymani J . Correlation of inflammatory biomarkers with the diversity of Bacteroidaceae, Bifidobacteriaceae, Prevotellaceae and Lactobacillaceae families in the intestinal microbiota of patients with end stage renal disease. Adv Med Sci. 2022; 67(2):304-310. DOI: 10.1016/j.advms.2022.07.004. View

10.

. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2019; 7(1):1-59. PMC: 6340919. DOI: 10.1016/j.kisu.2017.04.001. View

11.

Hou H, Yin J, Jiang X . Smart Patterned Surface with Dynamic Wrinkles. Acc Chem Res. 2019; 52(4):1025-1035. DOI: 10.1021/acs.accounts.8b00623. View

12.

Yang T, Richards E, Pepine C, Raizada M . The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease. Nat Rev Nephrol. 2018; 14(7):442-456. PMC: 6385605. DOI: 10.1038/s41581-018-0018-2. View

13.

Zhang W, Xu Y, Mu X, Li S, Liu X, Lei Z . Research Progress of Polysaccharide-Based Natural Polymer Hydrogels in Water Purification. Gels. 2023; 9(3). PMC: 10048097. DOI: 10.3390/gels9030249. View

14.

Pocivavsek L, Ye S, Wagner W, Tzeng E, Pugar J, ODea R . Topography Driven Surface Renewal. Nat Phys. 2024; 14(9):948-953. PMC: 11271749. View

15.

Lewis J, Sika M, Koury M, Chuang P, Schulman G, Smith M . Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2014; 26(2):493-503. PMC: 4310662. DOI: 10.1681/ASN.2014020212. View

16.

Azpiazu D, Gonzalo S, Gonzalez-Parra E, Egido J, Villa-Bellosta R . Role of pyrophosphate in vascular calcification in chronic kidney disease. Nefrologia (Engl Ed). 2017; 38(3):250-257. DOI: 10.1016/j.nefro.2017.07.005. View

17.

Carrillo-Lopez N, Panizo S, Alonso-Montes C, Martinez-Arias L, Avello N, Sosa P . High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease. Nephrol Dial Transplant. 2018; 34(6):934-941. DOI: 10.1093/ndt/gfy287. View

18.

Vervloet M, van Ballegooijen A . Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney Int. 2018; 93(5):1060-1072. DOI: 10.1016/j.kint.2017.11.036. View

19.

Hou H, Hu K, Lin H, Forth J, Zhang W, Russell T . Reversible Surface Patterning by Dynamic Crosslink Gradients: Controlling Buckling in 2D. Adv Mater. 2018; :e1803463. DOI: 10.1002/adma.201803463. View

20.

Ogata H, Takeshima A, Ito H . An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles. Expert Opin Drug Saf. 2022; 21(7):947-955. DOI: 10.1080/14740338.2022.2044472. View